NTRC 0652-0 / Crossfire Oncology - LARVOL DELTA

LCK inhibitor NTRC-0652-0 shows synergy with EGFR inhibition in cholangiocarcinoma (Bioworld) - "It is known that tyrosine-protein kinase LCK activates Yes-associated protein (YAP), which is a well-known known oncogene in CCA. Researchers have hypothesized LCK as a potential therapeutic target in CCA."

Preclinical • Biliary Tract Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology